Loading
Yarrow Bioscience, Inc. Stock: price and insider trades · United States
US·Mcap US$170.4M
No insider purchase over the last 90 days. The latest was filed 16 Jan 2025.
Yarrow Bioscience, Inc.: what insiders have been doing
Every trade that managers of Yarrow Bioscience, Inc. disclose to SEC (Form 4) is tracked on this page. The last twelve months, up to 18 October 2026, brought 13 filings signed by 5 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 13 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 7 purchases and 4 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 570,000 USD and net income of -26.5 m USD.
Over the last twelve months, not one insider purchase of Yarrow Bioscience, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
123
Thresholds
n/a
Buy Volume
€224,210
7 ops. · all time
Sell Volume
€4M
4 ops. · all time
Who traded when
BuySalePatrick G. Lepore1 buy
Since the insiders bought
- -86.1%Entry US$27.00 · Close at T+365 US$3.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.31
Analyst consensus
2 analysts1.08/5
US$56.00Target US$57.00(+211%)US$58.00
Income statement
RevenueUS$488.8k
EBITDA-US$124.1M-25383% margin
Net income-US$22.7M0.0% margin
Valuation
PER (forward)-11.1x
P/Book5.4x
Beta2.08
Balance sheet & cash
Market capUS$170.4M
Total debtUS$11.5M
Free Cash Flow-US$88.1M
Debt / Equity2%
Profitability & ownership
ROE-40.0%
ROA-25.8%
% insiders2.0%
% institutions38.2%
Last declaration on 30 July 2026
Declarations123 total
133,290 shares0Common StockSEC:0001104659-26-088665:0
22,516 shares@ US$0.89760.11% mcap15.3% of flowCommon StockSEC:0001727809-26-000008:0
15,405 shares@ US$0.89760.072% mcap18.4% of flowCommon StockSEC:0001727756-26-000008:0
22,516 shares@ US$0.89760.11% mcap24.2% of flowCommon StockSEC:0001867033-26-000008:0
79,391 shares@ US$0.89760.37% mcap14.8% of flowCommon StockSEC:0001727794-26-000010:0
14,232 shares@ US$0.59751.7% of flowCommon StockSEC:0001727794-26-000004:0
2,876 shares@ US$0.59752.3% of flowCommon StockSEC:0001727756-26-000004:0
4,007 shares@ US$0.59751.8% of flowCommon StockSEC:0001727809-26-000004:0
4,007 shares@ US$0.59752.8% of flowCommon StockSEC:0001867033-26-000004:0
7,858 shares@ US$0.58015.3% of flowCommon StockSEC:0001867033-26-000002:0
12,684 shares@ US$0.58011.5% of flowCommon StockSEC:0001727794-26-000002:0
2,448 shares@ US$0.58011.8% of flowCommon StockSEC:0001727756-26-000002:0
3,579 shares@ US$0.58011.5% of flowCommon StockSEC:0001727809-26-000002:0
3,420 shares@ US$0.3351.3% of flowCommon StockSEC:0001867033-25-000003:0
2,453 shares@ US$0.3351.1% of flowCommon StockSEC:0001727756-25-000003:0
3,581 shares@ US$0.3350.9% of flowCommon StockSEC:0001727809-25-000003:0
12,676 shares@ US$0.3350.9% of flowCommon StockSEC:0001727794-25-000003:0
12,676 shares@ US$1.654.2% of flowCommon StockSEC:0001415889-25-019056:0
2,453 shares@ US$1.655.2% of flowCommon StockSEC:0001415889-25-019058:0
3,581 shares@ US$1.654.3% of flowCommon StockSEC:0001415889-25-019057:0
3,420 shares@ US$1.656.5% of flowCommon StockSEC:0001415889-25-019059:0
8,681 shares@ US$0.811.5% of flowCommon StockSEC:0001415889-25-015382:0
1,145 shares@ US$0.810.7% of flowCommon StockSEC:0001415889-25-015383:0
6,044 shares@ US$1.5813.4% of flowCommon StockSEC:0001415889-25-009632:0
8,828 shares@ US$1.5811.1% of flowCommon StockSEC:0001415889-25-009631:0
25 of 123 declarations
About Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc. is a company listed on the XNAS market, specializing in the development of biopharmaceutical solutions. It focuses on innovation in the life sciences sector.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
